p53 protein expression in transitional cell carcinoma of the bladder - Experience of the University of Malaya Medical Centre

Asian Journal of Surgery

Volumn 26, Issue 1, 2003, Pages 31-36

  Ong, Teng A ^a   Peh, Suat C ^a   Goh, Kenny S K ^a   Naicker, Mala S ^a   Khan, Afzal F ^a   Chua, Beng C ^a   Razack, Azad ^a  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CIGARETTE SMOKING; COHORT ANALYSIS; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; BLADDER OBSTRUCTION; CANCER STAGING; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NECK OBSTRUCTION;

EID: 0037504431     PISSN: 10159584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1015-9584(09)60212-8     Document Type: Article

References (51)

1. Rabbani F, Cordon-Cardo C. Mutation of cell cycle regulators and their impact on superficial bladder cancer. In: Loughlin KR, ed. The Urologic Clinics of North America. Philadelphia: WB Saunders Company, 2000:83-102.
2. Harris CC, Holstein M. Review articles: clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
3. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-3.
4. Montenarh M. Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 1992;7:1673-80.
5. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF-1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
6. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early upregulation of Bax expression by p53 but not TGFb1: a paradigm for distinct apoptotic pathways. Oncogene 1994;9:1791-8.
7. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in-vitro and in-vivo. Oncogene 1994;9:1799-805.
8. Olumni AF. A critical analysis of the use of p53 as a marker for management of bladder cancer. In: Loughlin KR, ed. The Urologic Clinics of North America. Philadelphia: WB Saunders Company, 2000:83-102.
9. Lane DP. P53, the guardian genome. Nature 1992;358:15-6.
10. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
11. Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992;52:1393-8.
12. Wright C, Mellon K, Johnston P, et al. Expression of mutant p53, cerbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 1991;63:967-70.
13. Serth J, Kuczyk MA, Bokemeyer C, et al. P53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995;71:201-5.
14. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Molecular pathways to TCC of bladder. Cancer Res 1994;54:784-8.
15. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
16. Mora PT, Chandrasekaran K, Hoffman JC, Mcfarland VW. Quantitation of a 55K cellular protein: similar amount and instability in normal and malignant mouse cells. Mol Cell Biol 1992;2:763-71.
17. Rogel A, Popliker M, Webb CG, Oren M. P53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol Cell Biol 1985;5:2851-5.
18. Bokemeyer C, Kuczyk MA, Sehrt J. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1994;330:864-5.
19. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
20. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
21. Furihata M, Inoue K, Ohtsuki Y, et al. High risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 1993;53:4823-7.
22. Vet JAM, Bringuier PP, Poddighe PJ, et al. P53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994;70:496-500.
23. Abdel-Fatah R, Challen C, Griffiths TRL, et al. Alterations of of Tp53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of Tp53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998;77:2230-8.
24. Sidransky D, Von Eschenbach, Tsai YC, et al. Identification ofp53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
25. Tsai TC, Nichols PW, Hiti AL, et al. Allelic losses of chromosome 9, 11 and 17 in human bladder cancer. Cancer Res 1990;50:44-7.
26. Cordon-Cardo C, Dalbagni G, Saez GT, et al. P53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994;56:347-53.
27. Esrig D, Spruck CH III, Nichols PW, et al. P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
28. Siu LL, Banerjee D, Khurana RJ, et al. The prognostic role of p53, metallothionein, P-glycoprotein and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 1998;4:559-65.
29. Lacombe L, Dalbagni G, Zhang ZF, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: correlation to clinical outcome. J Clin Oncol 1996;14:2646-52.
30. Pages F, Flam TA, Vieillefond A, et al. P53 status does not predict initial clinical response to Bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J Urol 1998;159:1079-84.
31. Hruban RH, Riet VDP, Erozan YS, Sidransky D. Brief report: molecular biology and the early detection of carcinoma of the bladder - the case of Hubert H. Humphrey. N Engl J Med 1994;330:1276-8.
32. Werthman PE, Drazan KE, Rosenthal JT, et al. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 1996;155:753-6.
33. Glick SH, Howell LP, White RWD. Relationship ofp53 and bcl-2 to prognosis in muscle invasive transitional cell carcinoma of the bladder. J Urol 1996;155:1754-7.
34. Moch H, Sauter G, Mihatsch MJ, et al. P53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 1994;25:1346-51.
35. Nakopoulou L, Vourlakou C, Zervas A, et al. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998;29:146-54.
36. Popov Z, Hoznek A, Colombel M, et al. The prognostic value of of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472-81.
37. Hall PA, Ray A, Lemoine NR, et al. P53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991;338:513.
38. Lipponen PK. Over-expression of P53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70.
39. Soini Y, Turpeenniemi-Hujanen T, Kamel D, A et al. P53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 1993;68:1029-35.
40. Uchida T, Wada C, Ishida H, et al. p53 mutations and prognosis in bladder tumors. J Urol 1995;153:1097-104.
41. Gardiner RA, Walsh MD, Allen V, et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumor progression. Br J Urol 1994;73:526-32.
42. Nakopoulou L, Constantinides C, Papandropoulos J, et al. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 1995;46:334-40.
43. Underwood MA, Reeves J, Smith G, et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 1996;77:659-66.
44. Thomas DJ, Robinson MC, Charlton R, et al. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol 1993;73:533-7.
45. Vet JAM, Bringuier PP, Schaafsma HE, et al. Comparison of p53 protein overexpression with p53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 1995;73:837-43.
46. th edition). St. Louis Missouri, Mosby Year Book Inc.; 1996;1195-202.
47. th edition). New York, Springer-Verlag, 1997:309-14.
48. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
49. Bernardini S, Adessi GL, Chezy E, et al. Influence of cigarette smoking on P53 gene mutations in bladder carcinomas. Anticancer Res 2001;21:3001-4.
50. Spruck CH III, Ridout WMIII, Olumi AF, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993;53:1162-6.
51. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384-90.